Genome-Wide Massively Parallel Sequencing of Formaldehyde Fixed-Paraffin Embedded (FFPE) Tumor Tissues for Copy-Number- and Mutation-Analysis

1The advance of second generation sequencing techniques (454 sequencing, the Illumina Genome Analyzer (Solexa), the SOLiD platform, the Polonator and the HeliScope Single Molecule Sequencer technology) enables us to investigate many “-omes” of patients material, such as genomes, transcriptomes, epigenomes and miRNAomes,,. The sequencing techniques are based on the amplification of single DNA molecules and thereby provide, in a sense, ‘digital’ information,,. They are considerably less error-prone to the ‘contamination’ between normal and diseased tissues and are especially advantageous for the analysis of tumor tissues.

2To date, cancer sequencing programs have relied on DNA isolated from fresh frozen tissues, access to which can be limited. The use of preserved material, i.e. from tissue banks, could help to avoid this limitation and would enable the reanalysis of diverse clinical trials. A common and convenient way to store tissues over long periods of time is to fix them in formaldehyde and embed them in paraffin. Large collections of diseased and normal tissues are stored at hospitals and provide an excellent source for molecular genetic studies. However, the recovery of nucleic acids from these tissue specimens is challenging. Not only does formaldehyde lead to crosslinkages between DNA or RNA and proteins, but it also results in the preparation of fragmented DNA. Both factors restrict diverse genetic techniques like polymerase chain reactions due to poor quantity, purity and length of the RNA and DNA.

3To take advantage of preserved patient tissue we investigated the sample quality requirements of formaldehyde-fixed and paraffin-embedded (FFPE) tissues and established a protocol for the application of massively parallel short-read sequencing approaches. We evaluated key variables of pre-fixation, fixation related and post-fixation processes that occur in routine medical service (e.g. degree of autolysis, duration of fixation and of storage) (Table 1). We also investigated the influence of tissue storage time on sequencing quality by using material that was up to 18 years old. Finally, we analyzed normal and tumor breast tissues using the Sequencing by Synthesis (Illumina Genome Analyzer) technology to simultaneously localize genome-wide copy number alterations and to detect genomic variations such as substitutions and point-deletions and/or insertions in FFPE tissue samples.

4For the comparison of snap frozen and FFPE tissue DNA we prepared breast tissue samples from one patient, divided the tissue in seven equal amounts and preserved them either as snap frozen or as FFPE tissue with ischemic times ranging from 20 min. to over 6 hours and fixation times from 24 to 72 hours (Table 1). After six months storage time, DNA was extracted, quality controlled by aid of a Bioanalyzer array and sequenced with the Sequencing by Synthesis technology (SBS). Test DNA extractions using the QIAamp, Arcturus PicoPure and Macherey-Nagel DNA extraction kits yielded equally successful sequencing results and therefore further experiments were performed according to the Qiagen protocol (data not shown). Tissue storage conditions followed those used most frequently in routine pathology department protocols. The sequencing resulted in approximately 3 to 5 million reads with 2 to 3 million mappable unique fragments per sample (Table 2). For a visualization of the fragment distributions we divided each chromosome in 300 equal sized parts (‘bins’) and calculated the fragment number for each bin. Using these 300 bins per chromosome we found a very similar distribution of fragments over all chromosomes (Figure 1) for snap frozen as well as for FFPE tissue DNA. Comparing the readcounts per set unit (bin) for snap frozen and FFPE tissue as a measure of coverage coherence, we calculated the Pearson correlation coefficient and found a median correlation of bincounts of 0.82 for snap frozen and FFPE tissues. We also used genomic bin sizes of 50, 100, 250, 500 and 1000 Kb and stratified the correlation coefficients by the GC content of the bins (Supplementary Figure S1). Bins with the most common GC content of approximately 40% have correlation values of approximately 0.97. The dependency of correlation values from GC content is decreasing with larger bin sizes though and is therefore likely a consequence of low coverage. Similar findings were observed for technical replicates (Supplementary Figure S2). In both cases the majority of correlation coefficients are above 0.6 and the variability decreases with increasing bin sizes. Thus, overall fragment numbers, aligned fragments and chromosome-wise coverage are similar for snap frozen and FFPE tissues, proving that fresh FFPE tissues can be used for high throughput re-sequencing approaches.

5Most of the tissues stored in biobanks are several years old and clinical trials date back to at least ten year collection times. Therefore, it would be highly desirable to include tissue samples that have been stored long-term for genome-wide sequencing techniques. In addition, studies of rare clinical diseases such as Von Hippel-Lindau or Li-Fraumeni syndrome would become more feasible to perform. Sequencing by Synthesis (SBS) of snap frozen - and FFPE preserved tissue samples that were 14 and 18 years old resulted in approximately 1 million and 4 million aligned reads with an even distribution over all chromosomes. Median correlation of bincounts for snap frozen and FFPE tissue was found to be very similar to recent tissue values at 0.84. Thus, tissue storage time has a minor influence on sequence quality. It would be interesting to analyze even older material in the same manner.

6In addition to normal tissue samples, we also used tumor tissue samples to investigate copy number alterations (CNA) and mutation frequencies. CNAs are useful parameters for tumor classifications and – as recently introduced in genetic counseling procedures – as diagnostic tool for children with mental retardation of unknown origin,. The identification of tumor mutations is essential for the layout of a calculated chemotherapy. For example, tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are only efficient in patients without K-ras mutations. Up to now the detection of CNAs and mutations required that two different techniques be employed in routine clinical diagnostics: CNAs are determined by comparative genomic hybridization (CGH) arrays and mutations are found by conventional sequencing techniques. With the power of second generation sequencing techniques, both sets of information will be achieved in one process. Along this line, we provide here the combined data for breast tumor tissues, both snap frozen as well as FFPE tissues, using single SBS approaches. For these experiments, breast tumor tissues were enriched for at least 70% tumor cell content by macro-dissections. DNA libraries for the Illumina Genome Analyzer (Solexa) were then prepared and sequenced. We received approximately 1 million reads with 0.5 million unique mappable fragments. Using the DNAcopy software in R we found gains of DNA on chromosome 8 and 20 (Figure 2A). For chromosome 8, a fine-mapping of copy number alterations revealed gain of DNA between the chromosomal localizations 90.32 Mb and 146.27 Mb with a small disruption between 137.06 Mb–139.4 Mb (Figure 2B). The CNAs found were identical for snap frozen - and FFPE – material. They also corresponded to frequent alterations found in breast tumors in general, underlining the reliability of the sequencing technique.

7Using one eighth of each Illumina Genome Analyzer (Solexa) run sequencing capacity, the resolution with regard to CNAs lies at approximately 15 Kb with 10 fragments per bin and can be easily improved by additional sequencing. In comparison, the resolution of the 244 K Array from Agilent, a frequently used array in clinical settings, lies at approximately 45 Kb with 5 oligos. In addition to CNA information, second generation sequencing allows one to investigate genomic alterations, such as substitutions, deletions and insertions and therefore will be a basic tool for routine clinical diagnostics in the future.

8In addition to CNAs, we also calculated nucleotide exchange (NE) rates for all samples. In general, we found a NE probability of 0.1 to 0.5% per aligned sequence read (Table 2). Approximately 12% to 33% of NEs found were located in dbSNP and can therefore be classified as known SNPs. We also compared the NEs pairwise under consideration of an at least 8fold coverage and identified up to 90% ‘common SNPs’ for samples ID-02.15 and ID-02.48 (Table 2). The absolute amount of called SNPs appears to be higher for FFPE tissues with a lower rate of known SNPs identified. This is most likely due to DNA damage of the FFPE samples. By increasing the sequence depth of the samples the overlap between NEs for snap frozen and FFPE DNA increases, suggesting that with an increase of sequence coverage the rate of false positive calls in FFPE can be minimized (Supplementary Figure S3). The amount of specific NE rates such as A to G or C to A varies between 5% and 14%. However, the amounts of specific NE rates were comparable in different sequencing settings with an average standard deviation of 0.7%. The reproducibility of specific NE rates was also found in the comparison of snap frozen and FFPE tissue DNA as shown in Figure 3 and Table 3. A higher variability of NEs in FFPE tissue samples is largely due to extended fixation times since we have included all available sequencing data from table 1 in our calculations. For both tissue preparation techniques we found corresponding NE rates, suggesting that FFPE tissues can also be used for mutational analyses. Filtering for homozygous mutations, we found approximately 5% of all SNPs with sequencing coverage rates greater than 8-fold and we were able to repeatedly detect approximately 90% of the mutations in both snap frozen and FFPE tissue preparations. As expected, the absolute amount of known SNPs increased with the number of sequencing fragments aligned for both snap frozen as well as FFPE tissues. This again demonstrates the applicability and scalability of second generation sequencing techniques for the detection of mutations in FFPE tissues.

9Taken together, our results illustrate that DNA extracted from FFPE tissue can be used for second generation re-sequencing approaches. We also demonstrated the possibility of gathering information about CNAs and mutations with one single sequencing effort from snap frozen as well as FFPE preserved tissue types and proved that the data obtained from both preparation methods is of comparable quality.

10In this paper, we investigated if new and archived FFPE tissues could be used in addition to snap frozen tissues for massively parallel sequencing and what requirements need to be fulfilled for their use. We conclude that DNA extracted from FFPE tissues can be used for Sequencing by Synthesis (SBS) and that neither an increase in ischemia time from 20 min. to over 360 min. nor a longer fixation time of up to 72 hours plays a major role in sequencing quality (Figure 1, Table 1). Overall, the percentage of unique mappable reads was in the same range for snap frozen and paraffin-embedded samples. In general, we see variations in mappable reads independent of the DNA source. However, for FFPE samples the variability might also be partly due to DNA damages resulting in more fragments with one or more mismatches. Even though the absolute numbers of unique alignments is slightly smaller for DNA extracted from FFPE tissues, the fragments are evenly distributed over the genome and cover all chromosomes. Furthermore, as demonstrated, FFPE tissue samples stored over 18 years in pathology departments can be successfully sequenced and integrated in re-sequencing programs. This provides an excellent opportunity to evaluate tissue samples which have been collected and stored in biobanks for clinical trials with anti cancer drugs. For instance, it has become evident that the response to inhibitors of receptor tyrosine kinases or inhibitors of downstream signaling molecules not only depends on the expression of the drug target itself but also on the presence of mutations or polymorphisms in functional domains of the target and its down stream signaling network.

11The power of large-scale sequencing techniques not only lies in the large amount of sequencing throughput but also in the possibility to gain multi-faceted data of genomic, epigenomic and transcriptomic origin.

12As an example of the type of genome-based information that can be obtained, we presented the successful calculation of copy number alterations and mutations from snap frozen as well as from FFPE breast tumor tissue. Copy number alterations in breast cancer tissue were found equally well in snap frozen and FFPE prepared tissue (Figure 2).

13A patient-wise comparison of snap frozen and FFPE tissues with regard to called mutations demonstrated concordance for 81 to 95% of mutations found in both preparation types given an eightfold coverage rate. The comparable mutation rates and frequencies for each transition and transversion again demonstrated the reproducibility of the sequencing results in different preparation settings (Table 2). The detection limit depended upon the coverage rate calculated for technical replicates of snap frozen and FFPE tissues (data not shown), indicating that the number of consistently detected mutations in both tissue preparations could be increased beyond 90%.

14Formalin-fixed and paraffin-embedded tissue has not been used in large-scale sequencing protocols. Our study demonstrated that it can be reliably employed for highly relevant clinical problems such as the combined investigation of CNAs and SNPs in scarce tissue samples.

15Our observation that long-term storage of samples has no significant negative effect on sequencing results implies that it is possible to re-evaluate FFPE-samples from participants in previous clinical trials. In this way, DNA sequence-based biomarkers might be established which discriminate responders and non-responders to therapy, thereby contributing to a better targeted and more efficacious application of new therapeutic treatments. In addition, the determination of CNAs as well as mutations is not only essential for tumor diagnosis, but is also required for the diagnosis of a diverse array of genetic disorders associated with deletions or gains of DNA such as trisomy 21 and microdeletions-syndrome CATCH22 or with mutations such as Marfan's Syndrome.

16In summary, our results illustrate that DNA extracted from FFPE tissue can be used for copy number analysis as well as mutation analysis. Determining CNAs and mutations with one single sequencing effort renders our method very efficient in terms of time and money. The applicability and scalability of second generation sequencing techniques is a major improvement for the analysis of archived tissue material from biobanks and will lead to the application of large-scale sequencing techniques as routine diagnostic tools in general genetic counseling and oncology.

17The study has been approved by the Ethical Committee of the Medical University of Graz (ethics statement #20-066 signed by Prof.Dr. P.H. Rehak and Prof. DDr. H.P. Kapfhammer). For new samples patients have given their written informed consent. For old samples (14 and 18 years old) no informed consent was available, therefore all samples and medical data used in this study have been irreversibly anonymized.

18Human tissues obtained during surgery were divided into several aliquots which were either snap frozen in methyl butane at the temperature of liquid nitrogen or fixed in 4% buffered (pH 7.4) formaldehyde for 24 and 72 hrs and embedded in paraffin using an automated embedding system immediately after surgery (<20 min cold ischemia time). To simulate the impact of cold ischemia – samples were kept for 1 hr, 3 hrs and 6 hrs in a humidified chamber at room temperature before freezing. The impact of long-term storage (1 yr compared to 14 yrs and 18 yrs) of FFPE samples was investigated in samples retrieved from the tissue bank of the Institute of Pathology.

19From frozen tissue samples cryo sections of 3 µm thickness were produced and stained with haematoxylin eosin to evaluate tumor cell content. Further cryo sections were collected and processed for DNA isolation using the QIAamp DNA Mini Kit (Qiagen), according to the manufacturer's instructions.

20DNA was isolated from FFPE samples after extraction of 3 µm thick paraffin sections in xylene and by using the QIAamp DNA Mini Kit (Qiagen) PicoPure DNA Extraction Kit (Molecular Devices) and the Macherey-Nagel DNA extraction protocol following the same protocol as applied for frozen samples.

21Preparation of the libraries and sequencing were performed using the Solexa sequencing platform (GenomeAnalyzer, Illumina) following the manufacturer's instructions. We randomly sheared 1,5 µg genomic DNA to fragments less than 800 bp. The fragmented DNA was end-repaired using T4 DNA polymerase and Klenow polymerase with T4 polynucleotide kinase activity to blunt end and phosporylate the 5′ ends. A 3′ overhang was created using a exonuclease negative Klenow fragment and Illumina adaptor oligonucleotides were ligated to the sticky ends. Ligation products were purified by an agarose gel electrophoresis and enriched for successfully ligated fragments with an 18-cycle PCR using sequencing primers on either end. Ligation products were then used for cluster generation and sequencing- by- synthesis using the Illumina Genome Analyzer (Solexa).

22Image Analysis and base calling were performed using Firecrest 1.9.5_14 and Bustard 1.9.5_14 and reads were aligned to the human genome (NCBI36) using Bowtie 0.9.7.1. The chromosomal coverage was determined by splitting each chromosome in equally sized regions (bins) and counting the reads that mapped equally to each bin. The coverage comparison of different FFPE preparation protocols was visualized using 300 bins per chromosome.

23To compare the read coverage of different samples across all chromosomes we counted uniquely mapped reads for five different binsizes (50 Kb, 100 Kb, 250 Kb, 500 Kb, 1 Mb). As metric of comparison we used the Pearson correlation coefficient on the counts per bin. In detail, we determined the Pearson coefficient for each chromosome separately and calculated the median across all chromosomes. Stratification of bincount correlation by GC content was done by calculating the Pearson correlation coefficient across all bins of a certain GC content independent of chromosomal location.

24Copy number analysis was done in R using the DNAcopy package. In short, DNA read frequencies were determined for bins of 120 Kb. The log2 frequency ratio of corresponding bins was calculated for tumor versus normal tissue. Median of ratios was centered to zero experiment wise. Log ratios were smoothed by DNAcopy using default values and copy number variation was detected by DNAcopy using a threshold of two standard deviations.

25Overall nucleotide exchanges were calculated using the Maq 0.7.1 software with default parameters for the steps cns2snp & SNPfilter. Homozygous mutations detected in snap frozen and FFPE prepared material with at least 8-fold coverage in both samples were then compared patient wise. For the determination of the detection limit homozygous mutations in technical replicates for snap frozen and FFPE were compared.